Mackay Memorial Hospital

Brim Biotechnology, Inc.

Ho, Tsung-chuan

Tsung-Chuan Ho

Yeou-Ping Tsao

Shou-Chuan Shih

Frank Wen-Chi Lee

Kuanyin Karen Lin

Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment of a retinal degenerative disease or tissue injury. Also disclosed herein are methods of treating a retinal degenerative disease or tissue injury, by administering to a subject in need of such treatment, a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Short synthetic peptides and their uses for treating retinal degenerative diseases and/or tissue injuries

A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.

Compositions comprising PEDF-derived short peptides and uses thereof

Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to dry eye syndrome, psoriasis vulgaris or multiple myeloma, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Short synthetic peptide and uses thereof

Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease, disorder and/or a condition related to inflammation. Also disclosed herein are methods of treating and/or preventing a disease, disorder and/or a condition related to inflammation, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Short synthetic peptide for the treatment and/or prophylaxis of autoimmune and inflammatory disorders

Disclosed herein are synthetic peptides and compositions comprising the same, for the treatment and/or prophylaxis of a disease or a condition related to angiogenesis. Also disclosed herein are methods of treating and/or preventing a disease or a condition related to angiogenesis, by administering to a subject in need of such treatment a composition containing a therapeutically effective amount of a synthetic peptide of the present disclosure.

Short synthetic peptide for treating diseases and/or conditions related to angiogenesis

Disclosed herein are synthetic peptides and compositions comprising the same for the treatment and/or prophylaxis of an ocular disease, particularly, dry eye disease. Also disclosed herein are methods of treating and/or preventing an ocular disease by administering to a subject in need of such treatment a composition containing a synthetic peptide of the present disclosure.

Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease

A method for treating alopecia and/or hair depigmentation includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-44 amino acid residues and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 16-35 of SEQ ID NO: 10. Also disclosed herein are pharmaceutical compositions containing the synthetic peptide; and uses thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in treating alopecia and/or hair depigmentation in a subject.

Use of PEDF-derived polypeptides for treating alopecia and/or hair depigmentation

A method for promoting muscle or tendon regeneration, and/or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9.

Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis

A method for preventing and/or ameliorating skin aging in a subject includes administering to the subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.

Use of PEDF-derived polypeptides for preventing and/or ameliorating skin aging

A method for treating osteoarthritis in a subject includes administering to a subject in need of such treatments a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1.

Use of PEDF-derived polypeptides for treating osteoarthritis

Disclosed herein is a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues. The synthetic peptide has at least 80% amino acid sequence identity to SEQ ID NO: 1, and includes at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. Also disclosed herein are compositions containing the synthetic peptide and applications thereof. According to various embodiments of the present disclosure, the synthetic peptide is useful in promoting stem cells proliferation or wound healing.

Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing

The present disclosure elucidates that 34-mer PEDF suppresses hepatic stellate cells (HSCs) from activation by diminishing the levels of alpha-smooth muscle actin (&#x3b1;-SMC), collagen type 1, and monocyte chemoattractant protein-1 (MCP-1); and 44-mer PEDF promotes liver regeneration process by enhancing the replication of liver-derived progenitor cells (LDPCs). Accordingly, methods and compositions directing to the new use of the 34-mer PEDF or 44-mer PEDF in patients suffering from liver cirrhosis are provided herein.

Growing community of inventors

Taipei, Taiwan

Tsung-Chuan Ho